Recent advances in the development of immunoadhesins for immune therapy and as anti-infective agents

Recent Patents on Anti-Infective Drug Discovery

Volumn 4, Issue 3, 2009, Pages 183-189

  Pérez de la Lastra, José M ^a   Kremer, Leonor ^b   de la Fuente, José ^a,c  

^a INSTITUTO DE INVESTIGACIÓN EN RECURSOS CINEGÉTICOS IREC CSIC UCLM JCCM   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Anti infective agents; Fc fusion protein; Fc quimera; Immune therapy; Immunoadhesin; Immunoregulatory

Indexed keywords

ABATACEPT; AFLIBERCEPT; ALEFACEPT; ANTIINFECTIVE AGENT; ATACICEPT; BAMINERCEPT; BELATACEPT; BRIOBACEPT; CD4 IMMUNOGLOBULIN; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; RILONACEPT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; MUTATION; PATENT; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION; VIRUS INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES, BLOCKING; CELL ADHESION; CELL ADHESION MOLECULES; COMMUNICABLE DISEASES; HUMANS; IMMUNOTHERAPY;

EID: 70350749898     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489109789318550     Document Type: Review

References (49)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48(1): 1-12.
2. Taylor PL, Wright GD. Novel approaches to discovery of antibacterial agents. Anim Health Res Rev 2008; 9(2): 237-246.
3. Casadevall A. Antibody-based therapies as anti-infective agents. Expert Opin Investig Drugs 1998; 7(3): 307-321.
4. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2(9): 695-703.
5. Ashkenazi A, Chamow SM. Immunoadhesins as research tools and therapeutic agents. Curr Opin Immunol 1997; 9(2): 195-200.
6. Chamow SM, Ashkenazi A. Immunoadhesins: Principles and applications. Trends Biotechnol 1996; 14(2): 52-60.
7. Jefferis R. Antibody therapeutics: Isotype and glycoform selection. Expert Opin Biol Ther 2007; 7(9): 1401-1413.
8. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6(5): 343-357.
9. Beck JT, Marsters SA, Harris RJ, Carter P, Ashkenazi A, Chamow SM. Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage. Mol Immunol 1994; 31(17): 1335-1344.
10. Terai M, Tamura Y, Otsuka E, Berd D, Mastrangelo MJ, Sato T. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: Immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother 2009; 58(8): 1307-1317.
11. Harris RJ, Wagner KL, Spellman MW. Structural characterization of a recombinant CD4-IgG hybrid molecule. Eur J Biochem 1990; 194(2): 611-620.
12. Anderson CL, Human IgG Fc receptors. Clin Immunol Immunopathol 1989; 53: S63-S71.
13. Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 1999; 29(8): 2613-2624.
14. Shields RL, Angela KN, Kyu H, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276(9): 6591-6604.
15. Idusogie EE, Presta LG, Gazzano-Santoro, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164(8): 4178-4184.
16. Idusogie EE, Pin YW, Leonard GP, et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166(4): 2571-2575.
17. Hinton PR, Mary GJ, Joanna MX, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006; 176(1): 346-56.
18. Vaccaro C, Jinchun Z, Raimund JO, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23(10): 1283-1288.
19. Ober, E.S.W.: US20070041907 (2007).
20. Larrick, J., William, K., Wycoff, L.: WO2001083529 (2001).
21. Celada, F.: WO92005799 & WO2001920416 (1992).
22. Benjamin LC, Allan JS, Madsen JC. Cytokines in immunity and allograft rejection. Crit Rev Immunol 2002; 22(4): 269-279.
23. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008; 19(1): 41-52.
24. Ashkenazi, A.J., Ward, R.H.R.: US190204 (1994).
25. Lutters BC, Leeuwenburgh MA, Appeldoorn CC, Molenaar TJ, Van Berkel TJ, Biessen EA. Blocking endothelial adhesion molecules: A potential therapeutic strategy to combat atherogenesis. Curr Opin Lipidol 2004; 15(5): 545-52.
26. Lasky, L.A., Baumhueter, S., Rosen, S.D., Singer, M.S.: US20080241143 (2008).
27. Massberg, S.D., Gawaz, M., Bültmann, A., Münch, G., Ungerer, M., Peluso, M.: WO03104282 (2003).
28. Bavington C, Page C. Stopping bacterial adhesion: A novel approach to treating infections. Respiration 2005; 72(4): 335-344.
29. Larrick, J.W., Wycoff, K.L.: US20020168367 (2002).
30. Staunton, D., Springer, E.T.A.: WO93006848 (1993).
31. Visintin, A., Goldenbock, D.T.: WO2007001332 (2007).
32. Larrick, J., William, K., Wycoff, L.: WO03064992 (2003).
33. Feldmann M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest 2008; 118(11): 3533-3536.
34. Jazayeri JA, Carroll GJ. Fc-based cytokines: Prospects for engineering superior therapeutics. BioDrugs 2008; 22(1): 11-26.
35. Gillies, S.D.: US5650150 (1994).
36. Harvill, E., Morrison, T.S.L.: WO030089 (1997).
37. Khawli LA, Hu P, Epstein AL. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Handb Exp Pharmacol 2008; (181): 291-328
38. Capon, D., Gregory, J.T.J.: WO89002922 (1989).
39. Arathoon, R., Carter, P.J., Merchant, A.M., Presta, L.G.: WO98050431 (1998).
40. Segal DM, Qian JH, Mezzanzanica D, et al. Targeting of antitumor responses with bispecific antibodies. Immunobiol 1992; 185(2-4): 390-402
41. Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248(1-2): 7-15.
42. Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9(7): 617-621.
43. Chamow SM, Zhang DZ, Tan XY, et al. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J Hematother 1995; 4(5): 439-446.
44. Chamow SM, Zhang DZ, Tan XY, et al. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells. J Hematother 1995; 4(5): 439-446.
45. Berg J, Lotscher E, Steimer KS, et al. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc Natl Acad Sci USA 1991; 88(11): 4723-4727.
46. Fanger MW, Morganelli PM, Guyre PM. Bispecific antibodies. Crit Rev Immunol 1992; 12(3-4): 101-124.
47. Bos R, Nieuwenhuizen W. The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: Why they are used and how they are made. Biotherapy 1992; 5(3): 187-199.
48. Buchwald UK, Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Des 2003; 9(12): 945-968.
49. Schmidt, S.R., Fusion-proteins as biopharmaceuticals - applications and challenges. Curr Opin Drug Discov Dev 2009; 12(2): 284-295.